VEGFA and neoplasm: It has long been known that humanized monoclonal anti-VEGF antibodies, such as bevacizumab, or small molecule tyrosine kinase inhibitors, such as sorafenib and sunitinib, did not increase the overall survival of RCC patients, who ultimately developed secondary (acquired) resistance and succumbed because of tumor relapse and metastasis.